Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) Director Ronald Plott acquired 18,300 shares of the company’s stock in a transaction dated Monday, November 9th. The stock was acquired at an average cost of $0.83 per share, with a total value of $15,189.00. Following the purchase, the director owned 60,300 shares of the company’s stock, valued at approximately $50,049. This trade represents a 43.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.
Ronald Todd Plott also recently made the following trade(s):
- On Monday, September 28th, Ronald Plott acquired 5,000 shares of Phio Pharmaceuticals stock. The shares were bought at an average price of $1.03 per share, for a total transaction of $5,150.00.
- On Wednesday, August 19th, Ronald Plott acquired 15,000 shares of Phio Pharmaceuticals stock. The shares were bought at an average cost of $1.14 per share, with a total value of $17,100.00.
Phio Pharmaceuticals Price Performance
NASDAQ:PHIO opened at $0.81 on Wednesday. The company has a market cap of $9.73 million, a price-to-earnings ratio of -0.67 and a beta of 0.93. The stock’s 50 day simple moving average is $0.96 and its two-hundred day simple moving average is $1.08. Phio Pharmaceuticals Corp. has a 1 year low of $0.75 and a 1 year high of $1.88.
Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, meeting the consensus estimate of ($0.36). As a group, analysts anticipate that Phio Pharmaceuticals Corp. will post -1.47 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on PHIO. Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, October 15th. HC Wainwright reiterated a “buy” rating on shares of Phio Pharmaceuticals in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Phio Pharmaceuticals has an average rating of “Hold” and a consensus price target of $14.00.
Check Out Our Latest Analysis on PHIO
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.
Read More
- Five stocks we like better than Phio Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
